Office of Regulatory Affairs
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
The Office of Regulatory Affairs (ORA) is the part of the United States FDA [2]that enforces the laws that govern food, drugs, medical devices, and other products that FDA regulates.
Organization
It is organised around 5 regions - Northeast (NER), Central (CER), Southeast (SER), Southwest (SWR) and Pacific (PAR). Each region is further divided into district offices. There are a total of 20 district offices, nineteen of which handle both imported and domestic products and one import only district (Southwest Import, referred to as "SWID"). Districts, with the exception of SWID, are referred to by a three letter name followed by "DO", such as MIN-DO for Minneapolis District. ORA also includes field laboratories which were historically part of the districts but are now independent entities. There are also specialty laboratories such as the Forensic Chemistry Center (FCC) and the Winchester Engineering and Analytical Center (WEAC).
Each district office consists of three branches reporting to a district director. The majority of the staff are part of an Investigations Branch that performs routine inspections of manufacturers and imported products, audits of recalls, complaint investigations, collections of samples, and other related tasks. These staff are mostly Consumer Safety Officers (CSOs, "Investigators") or Consumer Safety Inspectors (CSIs, "Inspectors"). ORA no longer routinely hire CSIs, most new staff are CSOs. These staff have a variety of administrative authorities and enforce the civil law requirements of the Food, Drug, and Cosmetic Act as well as parts of the Public Health Service Act. Some are also commissioned officers of the Public Health Service, but this does not generally affect day to day duties. These staff are generally technical or scientific and are not involved in criminal law enforcement which is handled by a separate branch of FDA called OCI, though many criminal investigations are started by ORA referring a case to OCI.
The district offices also include a Compliance Branch. Compliance Officers handle the administrative authorities used in inspections, such as issuing Warning Letters. They also organizing civil litigation (such as a seizure or injunction) which is brought to the courts by the United States District Attorneys.
The final branch is an Admin Branch which handles budgeting, some aspects of payroll, and other administrative tasks. Regional and national experts are often located at district offices, but are not administratively part of those offices.
The districts also include resident posts, typically in major cities or at major border crossings. These are generally only Investigations Branch staff.
The ORA attempts to inspect all manufacturers of regulated items about once every two years. Other inspections, such as monitoring of clinical trials, are specifically initiated by headquarters and do not follow a set timeframe.
ORA operations are generally conducted according to the Investigations Operations Manual (IOM,available online) or a compliance program some available online.
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
